Avalo Therapeutics AVTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue recognized from milestones to date by Product | ||||||
| AVTX-301 Out-License | $0— | $0— | $0— | $0— | $0— | |
| AVTX-406 License Assignment | $0— | $0— | $0— | $0— | $0— | |
| Annual base rent by Geography | ||||||
| Maryland | $800K0.0% | $800K0.0% | $800K0.0% | $800K0.0% | $800K0.0% | |
| Pennsylvania | $800K0.0% | $800K0.0% | $800K— | $800K— | $800K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Avalo Therapeutics break its business down?
- Avalo Therapeutics (AVTX) reports revenue recognized from milestones to date by product across 2 parts — AVTX-301 Out-License and AVTX-406 License Assignment. Each is extracted from the segment footnotes and tracked over time.
- Where does Avalo Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Avalo Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
